Skip to content
lifestyle.ucconnection.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Calidi Biotherapeutics, Inc
Calidi Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
November 13, 2026
Calidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors into Localized TCE Biofactories
October 27, 2026
Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026
October 19, 2026
Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency
September 25, 2026
Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
September 17, 2026
Calidi Biotherapeutics to Present at H.C. Wainwright Global Investment Conference
September 8, 2026
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 13, 2026
Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference
July 27, 2026
Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit
June 24, 2026
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
June 23, 2026
1
2
Next Page
→